Pharming Group (CHIX:PHARMa)
€ 0.7515 0 (0%) Market Cap: 501.38 Mil Enterprise Value: 468.90 Mil PE Ratio: 0 PB Ratio: 2.65 GF Score: 81/100

Pharming Group NV and Orchard Therapeutics PLC Announce Collaboration to Develop and Commercialize Ex Vivo Autologous HSC Gene Therapy for Hereditary Angioedema Call Transcript

Jul 01, 2021 / 12:00PM GMT
Release Date Price: €1
Operator

Welcome, everyone, to today's joint analyst call, Orchard Therapeutics and Pharming Group. My name is Simona, and I will be your coordinator today. (Operator Instructions)

I will now hand you over to your host, Sijmen de Vries, Chief Executive Officer of Pharming Group, to begin. Sijmen, please go ahead.

Sijmen de Vries
Pharming Group N.V. - CEO & Executive Director

Thank you very much. Ladies and gentlemen, good afternoon to this joint analyst call. And before I will be saying something, I would like to point out to the next slide, the forward-looking statement slide because we will be making some forward-looking statements about our future plans and development plans, clinical results and other future conditions. And I would like to refer to our website for further information into the SEC statements.

That brings me to introducing my colleagues here today. If everything is correct, you should see some beautiful pictures now of Dr. Anurag Relan, our new Chief Medical Officer; my colleague, Dr. Bobby Gaspar, the CEO of Orchard

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot